Sedative effects and serum drug concentrations of oxymorphone and metabolites after subcutaneous administration of a liposome-encapsulated formulation in dogs.
Smith
L J
LJ
Department of Surgical Sciences, School of Veterinary, University of Wisconsin, 2015 Linden Drive, Madison, WI 53706, USA. smith@svm.vetmed.wisc.edu
Krugner-Higby
L
L
Trepanier
L A
LA
Flaska
D E
DE
Joers
V
V
Heath
T D
TD
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D000818:Animals; D004285:Dogs / Q000378:metabolism* / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004337:Drug Carriers / Q000008:administration & dosage; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D007279:Injections, Subcutaneous / Q000662:veterinary; D008081:Liposomes / Q000008:administration & dosage; D008297:Male; D010111:Oxymorphone / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics* / Q000494:pharmacology; D012119:Respiration / Q000187:drug effects
D000701:Analgesics, Opioid; D004337:Drug Carriers; D006993:Hypnotics and Sedatives; D008081:Liposomes; D010111:Oxymorphone